Innovent Entered into Clinical Trial Collaboration and Supply Agreement with Merck KGaA to Evaluate IBI351 + Erbitux (cetuximab) for KRASG12C-Mutated NSCLC in China
- The companies collaborated to evaluate IBI351 (GFH925) + cetuximab (ERBITUX) in the P-Ib trial for NSCLC patients harboring KRASG12C mutation in China
- Innovent will be responsible to conduct a P-Ib study to evaluate the anti-tumor activity & safety of IBI351 + cetuximab while Merck will provide clinical drug supplies of cetuximab. IBI351 is currently being evaluated in a single-arm registrational trial in previously-treated advanced NSCLC patients with KRASG12C mutation in China with an expected NDA filing at the end of 2023
- Cetixumab, an IgG1 mAb targeting the EGFR received market authorization in ~100 countries globally for RAS wild-type metastatic colorectal cancer & for SCCHN
Ref: Innovent | Image: Innovent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.